69 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
28
SAR Exploration Guided by LE and Fsp(3): Discovery of a Selective and Orally Efficacious ROR¿ Inhibitor.
Central Pharmaceutical Research Institute
52
Small molecule inhibitors targeting activator protein 1 (AP-1).
University of Texas Medical Branch
23
Design, synthesis, and structure-activity analysis of isoform-selective retinoic acid receptor beta ligands.
Acadia Pharmaceuticals
4
Retinoid receptor subtype-selective modulators through synthetic modifications of RARgamma agonists.
Universidade De Vigo
8
Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
Aristotle University of Thessaloniki
30
Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists.
Phenex Pharmaceuticals
1
Identification of a chromone-based retinoid containing a polyolefinic side chain via facile synthetic routes.
Temple University
6
Synthesis and structure-activity relationships of potent conformationally restricted retinoid X receptor ligands
TBA
11
Synthesis and biological activity of 1,2,3,4-tetrahydroquinoline and 3,4-(1H)-dihydroquinolin-2-one analogs of retinoic acid
TBA
6
Synthesis and receptor binding affinity of conformationally restricted retinoic acid analogues
TBA
6
Synthesis of highly potent RXR-specific retinoids: The use of a cyclopropyl group as a double bond isostere
TBA
8
Synthesis and pharmacological activity of conformationally restricted, acetylenic retinoid analogs
TBA
11
Differential RXR & RAR activity of stilbene retinoid analogs bearing thiazole and imidazole carboxylic acids
TBA
10
Novel non-carboxylic acid retinoids: 1,2,4-oxadiazol-5-one derivatives.
University of Lille
70
Structure-Based Design and Optimization Lead to the Identification of a Novel Potent sEH Inhibitor with PPARγ Partial Agonist Activity against Inflammatory and Metabolic-Related Diseases.
Shenyang Pharmaceutical University
5
Halogenated retinoid derivatives as dual RARα and RXRα modulators for treating acute promyelocytic leukemia cells.
Xiamen University
1
LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2.
Eli Lilly
28
Strategies for developing retinoic acid receptor alpha-selective antagonists as novel agents for male contraception.
University of Minnesota
6
Synthesis and structure-activity relationships of a new series of retinoid-related biphenyl-4-ylacrylic acids endowed with antiproliferative and proapoptotic activity.
Università
83
Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.
Indian Institute of Technology (B.H.U.)
11
Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.
University of Maryland
18
Design and synthesis of novel RXR-selective modulators with improved pharmacological profile.
Ligand Pharmaceuticals
17
Design, synthesis, and structure-activity relationship studies of novel 6,7-locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic acids.
Ligand Pharmaceuticals
7
Retinoic acid receptor ligands based on the 6-cyclopropyl-2,4-hexadienoic acid.
Ligand Pharmaceuticals
7
Synthesis and biological activity of retinoic acid receptor-alpha specific amides.
Allergan
4
Enantioselective syntheses of potent retinoid X receptor ligands: differential biological activities of individual antipodes.
Allergan
1
Syntheses and evaluation of quinoline derivatives as novel retinoic acid receptor alpha antagonists.
Eisai
9
Phenylcyclohexene and phenylcyclohexadiene substituted compounds having retinoid antagonist activity.
Allergan
1
Syntheses and evaluation of naphthalenyl- and chromenyl-pyrrolyl-benzoic acids as potent and selective retinoic acid receptor alpha agonists.
Eisai
1
Novel retinoic acid receptor alpha agonists: syntheses and evaluation of pyrazole derivatives.
Eisai
32
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
Goethe University Frankfurt
12
Syntheses and structure-activity relationships of 5,6,7, 8-tetrahydro-5,5,8,8-tetramethyl-2-quinoxaline derivatives with retinoic acid receptor alpha agonistic activity.
Eisai
7
Structure-activity relationship studies of novel heteroretinoids: induction of apoptosis in the HL-60 cell line by a novel isoxazole-containing heteroretinoid.
Università
2
Heteroarotinoids inhibit head and neck cancer cell lines in vitro and in vivo through both RAR and RXR retinoic acid receptors.
University of Oklahoma Health Sciences Center
20
Discovery and lead optimisation of a potent, selective and orally bioavailable RARβ agonist for the potential treatment of nerve injury.
King'S College
3
Synthesis, structure-activity relationships, and RARgamma-ligand interactions of nitrogen heteroarotinoids.
University of Oklahoma Health Sciences Center
6
A new class of potent RAR antagonists: dihydroanthracenyl, benzochromenyl and benzothiochromenyl retinoids.
Allergan
4
Stereoselective synthesis and receptor activity of conformationally defined retinoid X receptor selective ligands.
Allergan
19
Synthesis of retinoid X receptor-specific ligands that are potent inducers of adipogenesis in 3T3-L1 cells.
Ligand Pharmaceuticals
10
Synthesis and characterization of heteroarotinoids demonstrate structure specificity relationships.
University of Oklahoma Health Sciences Center
8
Conformationally defined retinoic acid analogues. 4. Potential new agents for acute promyelocytic and juvenile myelomonocytic leukemias.
University of Alabama At Birmingham
11
Regulation of retinoidal actions by diazepinylbenzoic acids. Retinoid synergists which activate the RXR-RAR heterodimers.
University of Tokyo
8
Synthesis and structure-activity relationships of retinoid X receptor selective diaryl sulfide analogs of retinoic acid.
Allergan
4
Identification of the first retinoid X, receptor homodimer antagonist.
Ligand Pharmaceuticals
3
Discovery of novel retinoic acid receptor agonists having potent antiproliferative activity in cervical cancer cells.
Ligand Pharmaceuticals
11
Retinoic acid receptor beta,gamma-selective ligands: synthesis and biological activity of 6-substituted 2-naphthoic acid retinoids.
Pharmaceutical Research Institute
25
Synthesis, structure-affinity relationships, and biological activities of ligands binding to retinoic acid receptor subtypes.
Cird Galderma
17
Conformational effects on retinoid receptor selectivity. 1. Effect of 9-double bond geometry on retinoid X receptor activity.
Sri International
6
Synthesis of high specific activity [3H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties.
Ligand Pharmaceuticals
20
Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids.
Ligand Pharmaceuticals
10
Synthesis and structure-activity relationships of stilbene retinoid analogs substituted with heteroaromatic carboxylic acids.
Allergan
6
Conformationally defined 6-s-trans-retinoic acid analogs. 2. Selective agonists for nuclear receptor binding and transcriptional activity.
University of Alabama At Birmingham
2
Synthesis and characterization of a highly potent and effective antagonist of retinoic acid receptors.
Allergan
9
Discovery of a potent, orally available, and isoform-selective retinoic acid beta2 receptor agonist.
Acadia Pharmaceuticals
6
Identification of highly potent retinoic acid receptor alpha-selective antagonists.
Allergan
6
Probing biological activity through structural modelling of ligand-receptor interactions of 2,4-disubstituted thiazole retinoids.
Helwan University
34
Structure-based design of Trifarotene (CD5789), a potent and selective RARγ agonist for the treatment of acne.
Nestle Skin Health
3
Design and synthesis of a potent, highly selective, orally bioavailable, retinoic acid receptor alpha agonist.
King'S College
34
Indazole-based ligands for estrogen-related receptor α as potential anti-diabetic agents.
Janssen Research and Development
30
Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry.
St. John'S University
